ELMD at a glance
Electromed, Inc. (ELMD, SEC CIK 1488917) filed its latest 10-K annual report on August 25, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as September 3, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended June 30, 2026 (FY2026), Electromed, Inc. (ELMD) reported revenue of $73.8 million (up 15.3% from FY2025) and net income of $11.3 million. Diluted EPS was $1.30.
- As of September 30, 2026, 21 institutional investment managers tracked by SignalX reported holding Electromed, Inc. (ELMD) shares worth $54.6 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Cunniff James L. on June 8, 2026 of 7,003 shares at $36.25 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2026
- $73.8M
- +15.3% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 21 funds
- $54.6M · −3 vs prior quarter
- Latest 8-K
- Nov 16, 2026
- Item 5.07
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $73.8M, up 15.3% YoY driven by homecare growth: $66.6M (+16.3%), hospital $3.4M (+9.6%), distributor $3.3M (+12.7%)
- Gross margin 78.5% vs 78.1%; Operating income $13.9M (+43.7%) margin approx. 18.8% vs 15.1% in prior year
- Best segment: Homecare revenue $66.6M (+$9.3M); Worst: Other revenue $0.4M (-34.7%)
- Operating cash flow $9.7M; Capex $1.25M; Share repurchase $3.9M; Dividends not mentioned
- Fiscal 2027 risks: Supply chain constraints, inflationary component costs, geopolitical conflict; strategy to expand sales force and bronchiectasis market presence
Business Overview
- Core business model: Direct-to-patient and provider sales of SmartVest HFCWO airway clearance therapy systems, bypassing traditional HME channels
- New product introduction: SmartVest Clearway launched Nov 2022, featuring touchscreen interface, single-hose patented design, lighter <14 lb generator for enhanced patient experience
- Strategic emphasis shift: Increased focus on bronchiectasis market, growing 12% annually with underpenetrated ~16% therapy adoption in ~1 million diagnosed US patients
- Quantitative highlights: Fiscal 2026 revenue $73.4M US-based (95.3% homecare), 58 direct sales employees, R&D spend up to $1.31M (1.8% revenue), 197 employees total
- Noteworthy 2026 fact: Publication and presentation of recent 2023-2025 clinical studies validating HFCWO efficacy in bronchiectasis and COPD, underscoring under-prescription and growth opportunity
AI summary of the ELMD 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Smaller reporting company status: no Item 1A risk-factor disclosure required
- No newly added or materially updated risks disclosed in the fiscal 2026 10-Q
Management Discussion & Analysis
- Revenue $18.682M, up 10.6% YoY from $16.887M, led by homecare revenue of $17.506M, up 17.6%
- Gross margin 80.0% vs 78.1% YoY, operating margin 18.7% vs prior-year 15.8%
- Hospital revenue $716K, down 31.6%, worst-performing channel; homecare distributor revenue $366K, down 55.9%
- Operating cash flow $373K, investing outflow $202K, share repurchases $4.328M
- Fiscal 2027 liquidity viewed sufficient; headwinds include inflation, component shortages, tariffs, reimbursement, competition and credit-facility renewal risk
AI summary of the ELMD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.07: Submission of Matters to a Vote of Security Holders
- Seven director nominees elected for one-year terms, maintaining board size at seven
- Kathleen S. Skarvan received highest withholdings, 1,645,493, signaling comparatively weaker shareholder support
Item 2.02: Results of Operations and Financial Condition
- Fiscal first-quarter results announced for period ended September 30, 2026
- Press release furnished as Exhibit 99.1, containing the substantive financial results
Item 7.01: Regulation FD Disclosure
- Updated investor presentation furnished as Exhibit 99.2
- Presentation intended for investor and analyst meetings
Item EX-99.1: Item EX-99.1
- Q1 FY2027 revenue $18.7M, up 10.6%, marking the 16th consecutive quarter of year-over-year growth
- Direct homecare revenue rose 17.6% to $17.5M, supported by 63 sales representatives and $1.109M annualized revenue per representative
Item EX-99.2: Item EX-99.2
- Investor presentation highlights TTM revenue $75.6M, operating income $14.7M, cash $15.9M, and zero debt as of September 30, 2026
- Q1 FY2027 revenue rose to $18.7M from $16.9M, while diluted EPS increased to $0.32 from $0.25
Item 7.01: Regulation FD Disclosure
- Updated investor presentation signals refreshed messaging for upcoming investor and analyst meetings
- Press release announces Mr. Cunniff’s planned retirement, creating potential management-transition relevance for shareholders
Item 2.02: Results of Operations and Financial Condition
- Press release announces Electromed’s fourth-quarter and fiscal-year 2026 financial results
- Results cover the fiscal year ended June 30, 2026
Item EX-99.3: Item EX-99.3
- CEO Jim Cunniff plans retirement on or about April 2, 2027, with concurrent departure from the board
- National search underway with an executive search firm for his successor
Item 5.02: Departure/Appointment of Directors or Principal Officers
- CEO James L. Cunniff plans retirement effective on or about April 2, 2027
- Board beginning comprehensive external search for successor CEO
Item EX-99.2: Item EX-99.2
- FY26 revenue $73.8M, up from $64.0M, supporting continued double-digit organic growth
- Operating income $13.9M, up from $9.7M, with margin expanding to 18.8% from 15.1%
Item EX-99.1: Item EX-99.1
- FY2026 revenue reached a record $73.8M, up 15.3%, led by direct homecare growth of 16.3% to $66.6M
- Operating income rose 43.7% to $13.9M, with margin expanding to 18.8% from 15.1%, signaling strong operating leverage
AI summaries of ELMD 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ELMD
Don't miss the next ELMD filing
- Alerts as it files. A push when ELMD files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ELMD, by share count.
- Ask anything. An AI agent that reads every ELMD filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Cunniff James L. | F | Sep 1, 2026 | 2,671 | $27.10 |
| Nagel Bradley M. | F | Sep 1, 2026 | 1,102 | $27.10 |
| Nagel Bradley M. | A | Sep 1, 2026 | 4,900 | - |
| Nagel Bradley M. | A | Sep 1, 2026 | 9,600 | - |
| Nagel Bradley M. | F | Jun 30, 2026 | 674 | $42.30 |
| Cunniff James L. | Sell | Jun 8, 2026 | 7,003 | $36.25 |
| Cunniff James L. | Sell | Jun 8, 2026 | 1,026 | $37.77 |
| Cunniff James L. | Sell | Jun 8, 2026 | 1,671 | $36.80 |
Financial SummaryXBRL
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $64.0M | $73.8M |
| Gross Profit | - | $50.0M | $57.9M |
| Operating Income | - | $9.7M | $13.9M |
| Net Income | - | $7.5M | $11.3M |
| Gross Margin | - | 78.1% | 78.5% |
| Op. Margin | - | 15.1% | 18.8% |
| Net Margin | - | 11.8% | 15.3% |
| Balance Sheet | |||
| Total Assets | $52.2M | $53.8M | $66.3M |
| Equity | $44.5M | $43.2M | $54.0M |
| ROE | - | 17.4% | 20.9% |
| Per Share | |||
| EPS | - | $0.85 | $1.30 |
| Cash Flow | |||
| Operating CF | - | $11.4M | $9.7M |
| CapEx | - | $262K | $1.3M |
Source: XBRL data in Electromed, Inc. (ELMD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate ELMD share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 21 | $54.6M |
| Q2 2026 | 24 | $82.4M |
| Q1 2026 | 22 | $44.9M |
| Q4 2025 | 21 | $58.0M |
| Q3 2025 | 20 | $51.4M |
| Q2 2025 | 20 | $42.6M |
| Q1 2025 | 19 | $34.6M |
| Q4 2024 | 14 | $31.4M |
- Renaissance Technologies LLC+28.8K (+29%)
- Goldman Sachs Group+25.6K (+35%)
- Morgan Stanley+21.4K (+47%)
- Vanguard Portfolio Management LLC+19.8K (+24%)
- BlackRock+11.4K (+2%)
- Invesco Ltd−43.3K (-84%)
- Citadel Advisors LLC−30.4K (-72%)
- Bank of America Corp−28.8K (-76%)
- Two Sigma Investments−9.3K (-6%)
- AQR Capital Management−4.7K (-13%)
- Millennium Management−8.5K
- T. Rowe Price Group−4.9K
- FMR LLC (Fidelity)−2.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 161 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ELMD filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 16, 2026 | - | Analysis | - |
| 10-Q | Nov 10, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 10, 2026 | - | Analysis | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 10-K | Aug 25, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 25, 2026 | - | Analysis | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | May 19, 2026 | - | - | |
| 8-K | May 12, 2026 | - | Analysis | |
| 10-Q | May 12, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Feb 10, 2026 | - | - | |
| 10-Q | Feb 10, 2026 | Dec 31, 2025 | Analysis | |
| 8-K | Dec 18, 2025 | - | - | |
| 4 | Dec 3, 2025 | - | - | |
| 4 | Dec 3, 2025 | - | - | |
| 4 | Dec 3, 2025 | - | - | |
| 4 | Dec 3, 2025 | - | - | |
| 4 | Dec 3, 2025 | - | - | |
| 4 | Dec 3, 2025 | - | - | |
| 4 | Dec 3, 2025 | - | - | |
| 10-Q | Nov 12, 2025 | Sep 30, 2025 | Analysis | |
| 10-K | Aug 26, 2025 | Jun 30, 2025 | - |
Related Health Care companies
- AXGN · Axogen, Inc.Electromedical & Electrotherapeutic Apparatus
- BLFS · BIOLIFE SOLUTIONS INCElectromedical & Electrotherapeutic Apparatus
- CV · CapsoVision, IncElectromedical & Electrotherapeutic Apparatus
- CBLL · Ceribell, Inc.Electromedical & Electrotherapeutic Apparatus
- CNMD · CONMED CorpElectromedical & Electrotherapeutic Apparatus
- HYPR · Hyperfine IncElectromedical & Electrotherapeutic Apparatus
- ITGR · Integer Holdings CorpElectromedical & Electrotherapeutic Apparatus
- LIVN · LivaNova PLCElectromedical & Electrotherapeutic Apparatus
ELMD SEC filings: frequently asked questions
Which institutions hold ELMD stock?
As of September 30, 2026, the largest Electromed, Inc. (ELMD) holders among the 13F filers tracked by SignalX were BlackRock ($13.5 million), Vanguard Capital Management LLC ($8.1 million), Dimensional Fund Advisors ($5.1 million), Two Sigma Investments ($4.5 million), Renaissance Technologies LLC ($3.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ELMD's revenue in fiscal year 2026?
For the fiscal year ended June 30, 2026 (FY2026), Electromed, Inc. (ELMD) reported revenue of $73.8 million (up 15.3% from FY2025) and net income of $11.3 million. Diluted EPS was $1.30. The figures come from the XBRL data in the 10-K.
What did ELMD report in its latest 8-K?
Electromed, Inc. (ELMD) filed an 8-K on November 16, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). Seven director nominees elected for one-year terms, maintaining board size at seven.
What are the latest ELMD SEC filings?
Electromed, Inc. (ELMD) filed its latest 10-K annual report on August 25, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on September 3, 2026.
What is ELMD's SEC CIK number?
Electromed, Inc. (ELMD)'s SEC Central Index Key (CIK) is 1488917. EDGAR lists every ELMD filing under that number.
Ask anything about ELMD
The research agent reads ELMD's filings, financials, insider trades and 13F holders, then answers with sources.